SEC 13F Intelligence

Managers / Q3 2024 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$2.0B
Q3 2024
Positions
68
Filings on Record
27
2019–present window
Filed
Nov 14, 2024
original filing

Summary

Boxer Capital, LLC reported $2.0B in U.S.-listed holdings across 68 positions for Q3 2024.

Its largest position, RVMD, represents 9.5% of the portfolio.

Compared with Q2 2024, the fund opened 12 new positions and exited 5.

Portfolio Metrics

Turnover
+9.5%
vs prior filed quarter
Top-10 Concentration
+54.9%
share of reported value
Largest Position
+9.5%
Revolution Medicines
New / Exited
12 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 82.0%ADR: 10.5%Other: 7.6%Equity WRT: 0.0%
  • Common Stock · 82.0% · $1.7B
  • ADR · 10.5% · $213M
  • Other · 7.6% · $154M
  • Equity WRT · 0.0% · $27,440

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TILInstil Bio IncNEW+355.5K355.5K+$24M$24M
KYMRKymera Therapeutics IncNEW+450.0K450.0K+$21M$21M
NRIXNurix Therapeutics IncNEW+563.1K563.1K+$13M$13M
Uniqure NVNEW+2.23M2.23M+$11M$11M
APGEApogee Therapeutics IncNEW+179.0K179.0K+$11M$11M
430Terns Pharmaceuticals IncNEW+752.0K752.0K+$6M$6M
SRRKScholar Rock Holding CorpNEW+750.0K750.0K+$6M$6M
SMMTSummit Therapeutics IncNEW+250.0K250.0K+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RVMDRevolution Medicines Inchistory →COM9.52%$194M4.28M
2TYRATyra Biosciences Inchistory →COM7.44%$152M6.45M
3NUVLNuvalent Inchistory →COM5.62%$115M1.12M
4ONCBeiGene Ltdhistory →SPONSORED ADR5.51%$112M500.0K
5CYTKCytokinetics Inchistory →COM NEW5.44%$111M2.10M
6SWTXUSDSpringworks Therapeutics Inchistory →COM5.38%$110M3.42M
7Merus N VCOM4.66%$95M1.90M
8SRPTSarepta Therapeutics Inchistory →COM3.98%$81M650.0K
9RNAGBPAvidity Biosciences Inchistory →COM3.89%$79M1.73M
10IDYAIdeaya Biosciences Inchistory →COM3.42%$70M2.20M
11TNGXTango Therapeutics Inchistory →COM3.10%$63M8.20M
12ARGXArgenx SEhistory →SPONSORED ADR2.66%$54M100.0K
13APLSUSDApellis Pharmaceuticals Inchistory →COM2.44%$50M1.73M
14AKROAkero Therapeutics Inchistory →COM2.36%$48M1.68M
15ANABAnaptysBio Inchistory →COM2.14%$44M1.30M
16AXSMAxsome Therapeutics Inchistory →COM1.76%$36M400.0K
172662247DiTeos Therapeutics Inchistory →COM1.48%$30M2.95M
18LEGNLegend Biotech Corphistory →SPONSORED ADS1.43%$29M600.0K
19GONGeron Corphistory →COM1.34%$27M6.00M
20Third Harmonic Bio IncCOM1.33%$27M2.00M
21RCKTRocket Pharmaceuticals Inchistory →COM1.33%$27M1.47M
22RCUSArcus Biosciences Inchistory →COM1.20%$24M1.60M
23TILInstil Bio Inchistory →COM NEW1.17%$24M355.5K
24XENEXenon Pharmaceuticals Inchistory →COM1.16%$24M600.0K
25IMVTImmunovant Inchistory →COM1.15%$24M825.0K
26KYMRKymera Therapeutics Inchistory →COM1.05%$21M450.0K
27SYRESpyre Therapeutics Inchistory →COM NEW1.01%$20M696.5K
28KURAKura Oncology Inchistory →COM0.96%$20M1.00M
294XC1Kalvista Pharmaceuticals Inchistory →COM0.90%$18M1.59M
30NKTXNkarta Inchistory →COM0.89%$18M4.03M
31ORICOric Pharmaceuticals Inchistory →COM0.87%$18M1.73M
32GPCRStructure Therapeutics Inchistory →SPONSORED ADS0.86%$18M400.0K
33FATEFate Therapeutics Inchistory →COM0.85%$17M4.96M
34ELVNEnliven Therapeutics Inchistory →COM0.84%$17M671.4K
35REPLReplimune Group Inchistory →COM0.83%$17M1.54M
36DAWNGBXDay One Biopharmaceuticals Ihistory →COM0.81%$17M1.19M
37CGEMCullinan Therapeuticshistory →COM0.75%$15M907.9K
38ARVNArvinas Inchistory →COM0.74%$15M608.6K
39CLYMEliem Therapeutics Inchistory →COM0.65%$13M2.60M
40RLAYRelay Therapeutics Inchistory →COM0.63%$13M1.82M
41NRIXNurix Therapeutics Inchistory →COM0.62%$13M563.1K
42Prothena Corp PLCSHS0.57%$12M690.0K
43Uniqure NVSHS0.54%$11M2.23M
44APGEApogee Therapeutics Inchistory →COM0.52%$11M179.0K
45OLMAOlema Pharmaceuticals Inc.COM0.38%$8M650.0K
46IOVAIovance Biotherapeutics IncCOM0.35%$7M750.0K
47IPSCCentury Therapeutics IncCOM0.33%$7M3.90M
48JSPRJasper Therapeutics IncCOM NEW0.32%$7M350.0K
49SANASana Biotechnology IncCOM0.32%$6M1.54M
50430Terns Pharmaceuticals IncCOM0.31%$6M752.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.